Parkinsonism
Slowness, stiffness, tremor, balance changes, or a shuffling gait. Symptoms may resemble Parkinson’s disease.
A trusted home for a rare diagnosis
Clear, evidence-based information and a connected community for people and families living with Perry syndrome.
Evidence-linked information · Worldwide resources · Family-centered language
Understanding the disease
Perry syndrome—also called Perry disease—is part of the spectrum of DCTN1-related neurodegeneration. It usually begins in adulthood and progresses over time.
Changes in the DCTN1 gene affect dynactin, a protein complex involved in transport inside nerve cells. The condition is usually inherited in an autosomal dominant pattern, meaning each child of an affected person has a 50% chance of inheriting the family variant. New (de novo) variants can also occur.
Figures describe published groups and cannot predict one person’s course.
GeneReviews ↗
Slowness, stiffness, tremor, balance changes, or a shuffling gait. Symptoms may resemble Parkinson’s disease.
Slower or shallow breathing—often first noticed during sleep. Symptoms may be subtle and need active monitoring.
Depression, loss of motivation, social withdrawal, anxiety, or other behavior and mood changes.
Unexpected and sometimes rapid weight loss, which can occur even when appetite remains good.
Diagnosis
No single symptom proves Perry syndrome. Diagnosis brings the clinical pattern, family history, respiratory assessment, and genetic testing together.
A neurologist—ideally a movement-disorders specialist—reviews movement symptoms alongside mood, weight, breathing, and family history.
A clinician may arrange overnight oximetry or a sleep study, blood-gas testing, lung-function testing, brain imaging, and other tests to exclude more common conditions.
Genetic counseling helps a family understand what testing can and cannot tell them, inheritance, consent, and implications for relatives.
A heterozygous pathogenic variant in DCTN1 can establish DCTN1-related neurodegeneration. Results should be interpreted by qualified genetics and neurology professionals.
2018 international consensus
All four major symptoms do not need to be present early. Published criteria describe definite, probable, and possible disease and should be applied by clinicians.
Open article ↗Practical checklist
Care and monitoring
There is currently no cure or proven disease-modifying treatment. Care focuses on symptoms, safety, function, comfort, and the priorities of the person and family.
A movement-disorders neurologist may consider dopaminergic therapy and physical, occupational, and speech therapy. Responses vary.
Pulmonology and sleep specialists can monitor for nocturnal hypoventilation and discuss non-invasive or other ventilatory support when appropriate.
Depression and suicidal thinking require active screening and treatment. Psychiatry, psychology, counseling, and caregiver support may all help.
Dietitians and speech-language pathologists can support calorie needs, swallowing safety, communication, and decisions about assisted nutrition.
Important: Medication and ventilation decisions must be individualized. GeneReviews advises avoiding respiratory depressants such as alcohol, narcotics, and benzodiazepines unless a treating clinician has specifically assessed their use.
Research library
A curated starting point for families, clinicians, and researchers. Links open the publisher or PubMed record.
Movement Disorders Clinical Practice
Parkinsonism & Related Disorders
European Journal of Neurology
Journal of Movement Disorders
Journal of Neurology, Neurosurgery & Psychiatry
Nature Genetics
Watch and listen
These educational resources contain medical discussion and, in the clinical videos, real symptoms. Viewer discretion is advised.
International Parkinson and Movement Disorder Society
Movement Disorders Clinical Practice / PubMed Central
Movement Disorders Clinical Practice / PubMed Central
Published family experiences
Because patient stories deserve consent and care, we do not invent testimonials. These anonymized summaries come from peer-reviewed case reports; first-person stories can be added only with a family’s permission.
After acute respiratory failure and diagnosis, respiratory intervention helped a woman remain highly independent at the published follow-up.
A man initially benefited from BiPAP and continued part-time work and recreational cycling until late in his illness.
Two close relatives with the same DCTN1 variant had very different movement symptoms and respiratory courses—showing why monitoring must be individualized.
Specialist connections
These contacts are drawn from peer-reviewed Perry syndrome work and current institutional profiles. Contact each center to ask about referrals, geography, telehealth, costs, and availability.
Mayo Clinic
Jacksonville, Florida · United States
Mayo Clinic neurologist, GeneReviews coauthor, and co-discoverer of the DCTN1 variants that cause Perry syndrome.
Contact or profile ↗Medical University of Gdańsk
Gdańsk · Poland
Neurologist and GeneReviews coauthor with extensive clinical and research publications on Perry syndrome.
Contact or profile ↗Hospital Universitario San Ignacio
Bogotá · Colombia
Neurologist at Hospital Universitario San Ignacio and coauthor of international Perry syndrome case and review studies.
Contact or profile ↗Fukuoka University Hospital
Fukuoka · Japan
A neurology department with a Parkinson’s clinic; its researchers led work on international Perry disease diagnostic criteria.
Contact or profile ↗This is an educational referral aid, not an endorsement or guarantee that a clinician is accepting patients. A local movement-disorders neurologist, genetic counselor, sleep specialist, or pulmonologist can also coordinate with an experienced center.
Common questions
No. It can cause parkinsonism, but it is a distinct inherited neurodegenerative condition linked to DCTN1 and has important respiratory, mood, and weight features.
Yes. Family history can be incomplete or unclear, and a new DCTN1 variant can occur. A genetics professional should interpret individual risk.
A pathogenic DCTN1 result is central, but results must be interpreted in the context of symptoms and family history. Some DCTN1 variants cause other neurologic conditions, and uncertain variants do not confirm a diagnosis.
Central hypoventilation can begin during sleep and may not be obvious to the person affected. Early respiratory assessment and follow-up can guide supportive treatment.
There is no cure at present. Symptom-focused care and respiratory support can improve quality of life and may extend survival; research is continuing.
Connect
Reach the foundation for support, research collaboration, story submissions, or help finding an appropriate clinical starting point.
Questions about resources, next steps, or connecting with the community.
support@perrysyndrome.comFor clinicians, investigators, publications, and research collaboration.
research@perrysyndrome.comPartnerships, media, accessibility, and other foundation questions.
contact@perrysyndrome.comIf you or someone you know may act on suicidal thoughts, contact local emergency services or a crisis line now. In the U.S. and Canada, call or text 988.